What is targeted radioisotope therapy done with?

The treatment combines two parts: a targeting molecule and a radioisotope. The targeting molecule binds to a particular marker on or near selected cancer cells. The attached radioisotope releases radiation close to those cells, with the aim of damaging their ability to grow. Lutetium-177 is one radioisotope used in this treatment approach.

The target must be present and suitable for the planned therapy, so imaging or other tests may be used before treatment. Targeted radioisotope therapy can be called radioligand therapy; PRRT is a related term used for treatments directed at peptide receptors.

Your team will explain the infusion or injection, checks needed beforehand, medicines given around treatment, and radiation-safety instructions for home. Drink fluids if advised, follow the team's guidance about contact with other people, and keep follow-up appointments for blood tests and organ monitoring.

Tell the treatment team about kidney problems, pregnancy, breastfeeding, medicines, and previous therapies. The exact schedule and precautions depend on the radioisotope, target, treatment plan, and your health.

Report persistent vomiting, severe diarrhoea, fever, unusual bleeding, marked weakness, reduced urine, or new swelling after treatment. Seek urgent help for trouble breathing, facial swelling, confusion, or severe chest pain. Use the emergency instructions provided by your treatment centre.

Ask which target your treatment uses, why the selected radioisotope is appropriate, how you will be monitored, what radiation precautions apply at home, and which symptoms require immediate contact.